Verition Fund Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-15,900
Closed -$2.43M 3341
2024
Q4
$2.43M Hold
15,900
0.01% 1425
2024
Q3
$3.08M Hold
15,900
0.02% 1155
2024
Q2
$3.69M Hold
15,900
0.02% 905
2024
Q1
$3.43M Buy
15,900
+10,200
+179% +$2.39M 0.02% 912
2023
Q4
$1.47M Sell
5,700
-96,800
-94% -$23.8M 0.01% 989
2023
Q3
$26.3M Buy
+102,500
New +$27.4M 0.31% 48
2022
Q4
Sell
-120,000
Closed -$32M 2165
2022
Q3
$32M Buy
120,000
+100,000
+500% +$21.2M 0.36% 35
2022
Q2
$4.08M Hold
20,000
0.08% 336
2022
Q1
$4.21M Buy
20,000
+10,000
+100% +$2.17M 0.05% 480
2021
Q4
$2.4M Buy
+10,000
New +$2.57M 0.02% 761

Other funds holding BIIB

Verition Fund Management's BIIB Position: Q1 2026 in Review

Verition Fund Management sold out of Biogen (BIIB) in Q1 2026, closing a stake of 18,523 shares — an estimated $3.26M sold.

Verition Fund Management first reported a position in BIIB in Q2 2013 and held it in 41 quarters. The position peaked at $54.5M in Q3 2023. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Verition Fund Management reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 18,523 Biogen shares in Q1 2026, an estimated $3.26M.
  • Verition Fund Management first reported a position in Biogen in Q2 2013 and held it in 41 quarters.
  • Verition Fund Management's Biogen position peaked at $54.5M in Q3 2023.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.